Cargando…

P62: An emerging oncotarget for osteolytic metastasis

Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a “vicious cycle” between tumor cells and bone cells (primarily the osteoclasts), which is media...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Yang, Zuozhang, Dong, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782024/
https://www.ncbi.nlm.nih.gov/pubmed/26998424
http://dx.doi.org/10.1016/j.jbo.2016.01.003
_version_ 1782419881442934784
author Zhang, Jing
Yang, Zuozhang
Dong, Jian
author_facet Zhang, Jing
Yang, Zuozhang
Dong, Jian
author_sort Zhang, Jing
collection PubMed
description Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a “vicious cycle” between tumor cells and bone cells (primarily the osteoclasts), which is mediated by secretory factors. The P62 adapter protein is a versatile multitasker between tumor cells and bone cells. The overexpression of P62 has been detected among a variety of tumors, playing positive roles in both tumorigenesis and metastasis. Moreover, P62 is an important modulator of the osteoclastogenesis pathway. Therefore, the ability of P62 to modulate tumors and osteoclasts suggests that it may be a feasible oncotarget for bone metastasis, especially for osteolytic metastasis. Recent research has shown that a P62 DNA vaccine triggered effective anti-tumor, anti-metastatic and anti-osteoporotic activities. Growing lines of evidence point to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we outline the different roles of P62 in tumor cells and osteoclasts, focusing on the P62-related signaling pathway in key steps of osteolytic metastasis, including tumorigenesis, metastasis and osteoclastogenesis. Finally, we discuss the newest observations on P62 as an oncotarget for osteolytic metastasis treatment.
format Online
Article
Text
id pubmed-4782024
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-47820242016-03-18 P62: An emerging oncotarget for osteolytic metastasis Zhang, Jing Yang, Zuozhang Dong, Jian J Bone Oncol Review Article Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a “vicious cycle” between tumor cells and bone cells (primarily the osteoclasts), which is mediated by secretory factors. The P62 adapter protein is a versatile multitasker between tumor cells and bone cells. The overexpression of P62 has been detected among a variety of tumors, playing positive roles in both tumorigenesis and metastasis. Moreover, P62 is an important modulator of the osteoclastogenesis pathway. Therefore, the ability of P62 to modulate tumors and osteoclasts suggests that it may be a feasible oncotarget for bone metastasis, especially for osteolytic metastasis. Recent research has shown that a P62 DNA vaccine triggered effective anti-tumor, anti-metastatic and anti-osteoporotic activities. Growing lines of evidence point to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we outline the different roles of P62 in tumor cells and osteoclasts, focusing on the P62-related signaling pathway in key steps of osteolytic metastasis, including tumorigenesis, metastasis and osteoclastogenesis. Finally, we discuss the newest observations on P62 as an oncotarget for osteolytic metastasis treatment. Elsevier 2016-02-03 /pmc/articles/PMC4782024/ /pubmed/26998424 http://dx.doi.org/10.1016/j.jbo.2016.01.003 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Zhang, Jing
Yang, Zuozhang
Dong, Jian
P62: An emerging oncotarget for osteolytic metastasis
title P62: An emerging oncotarget for osteolytic metastasis
title_full P62: An emerging oncotarget for osteolytic metastasis
title_fullStr P62: An emerging oncotarget for osteolytic metastasis
title_full_unstemmed P62: An emerging oncotarget for osteolytic metastasis
title_short P62: An emerging oncotarget for osteolytic metastasis
title_sort p62: an emerging oncotarget for osteolytic metastasis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782024/
https://www.ncbi.nlm.nih.gov/pubmed/26998424
http://dx.doi.org/10.1016/j.jbo.2016.01.003
work_keys_str_mv AT zhangjing p62anemergingoncotargetforosteolyticmetastasis
AT yangzuozhang p62anemergingoncotargetforosteolyticmetastasis
AT dongjian p62anemergingoncotargetforosteolyticmetastasis